The cardiac amyloidosis industry is witnessing transformative growth driven by advancements in diagnostics and therapeutic options addressing amyloid protein deposition in cardiac tissues. The evolving market dynamics reflect increasing investments in innovative treatments and a deepening understanding of disease pathology, signaling promising prospects for industry players. Emerging...